Table 1 The percentage of patients with positive expression and co-expression of the four CT antigens in patients with multiple myeloma
Samples groups | Percentage of patients with positive expression | ||||
|---|---|---|---|---|---|
MAGE-C1/CT7 | MAGE-A3 | MAGE-C2/CT10 | SSX-2 | ≥1 CT antigen gene | |
Newly diagnosed patients (n = 78) | 69 (88.5%) | 60 (76.9%) | 64 (82.1%) | 20 (25.6%) | 72 (92.3%) |
In remission (n = 113) | 76 (67.3%) | 51 (45.1%) | 52 (46.0%) | 12 (10.6%) | 90 (79.6%) |
Non-responders (n = 53) | 43 (81.1%) | 42 (79.2%) | 43 (81.1%) | 17 (32.1%) | 52 (98.1%) |
Relapsed patients (n = 12) | 10 (83.3%) | 9 (75.0%) | 9 (75.0%) | 7 (58.3%) | 10 (83.3%) |
*p-value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |
Percentage of patients with positive co-expression of the four CT antigens | |||||
0 gene | 1 gene | 2 genes | 3 genes | 4 genes | |
Newly diagnosed patients (n = 78) | 6 (7.7%) | 4 (5.1%) | 14 (17.9%) | 35 (44.9%) | 19 (24.4%) |
In remission (n = 113) | 23 (20.4%) | 32 (28.3%) | 22(19.5%) | 27 (23.9%) | 9 (8.0%) |
Non-responders (n = 53) | 1 (2.1%) | 9 (16.7%) | 6 (10.4%) | 23 (43.8%) | 14 (27.1%) |
Relapsed patients (n = 12) | 0 (.0%) | 0 (0%) | 2 (20.0%) | 3 (20.0%) | 7 (60.0%) |
*p-value | <0.01 | 0.01 | 0.42 | <0.01 | <0.01 |